“Patient Preference for Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam or Topical Suspension vs. Latest Topical Treatment in the PSO-INSIGHTFUL Study”, J of Skin, vol. 2, no. S1, p. S10, Feb. 2018, doi: 10.25251/skin.2.supp.10.